DYADIC INTERNATIONAL

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

09 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

07 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

26 Jul 2023 15:30:00 By Nasdaq GlobeNewswire

Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity

21 Jun 2023 07:33:24 By Nasdaq GlobeNewswire

Dyadic to Participate at Upcoming Events in June

01 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

10 May 2023 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Participate at Two Industry Events in May

10 May 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™

08 May 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

26 Apr 2023 15:30:00 By Nasdaq GlobeNewswire

Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform

18 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Present at World Vaccine Congress Washington 2023

30 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Reports 2022 Year End Results and Recent Company Progress

29 Mar 2023 15:00:00 By Nasdaq GlobeNewswire

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

15 Mar 2023 07:30:01 By Nasdaq GlobeNewswire

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

07 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

01 Mar 2023 07:30:05 By Nasdaq GlobeNewswire

Dyadic to Participate in Two Upcoming Investor Conferences

02 Feb 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

24 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic Announces Sale of Equity Interest in Alphazyme

19 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

04 Jan 2023 07:30:00 By Nasdaq GlobeNewswire

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

14 Dec 2022 07:30:00 By Nasdaq GlobeNewswire